Main Article Content

Authors

Two million two hundred thousand adults were newly HIV-infected in 2011, underscoring the urgent need for new, effective ways to prevent incident infections. Recently, the field of HIV prevention has gathered positive results from different strategies, among different populations, and with varying effect sizes, including the treatment of HIV-positive women and men in discordant couples, male circumcision of HIV-negative men in sub-Saharan Africa, a HIV vaccine evaluated in a community-based trial among HIV-negative men and women in Thailand, the use of vaginal gel formulation of TDF for HIV prevention in women in South Africa, pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) or emtricitabine and TDF (TDF-FTC) among HIV-1-serodiscordant heterosexual couples from Kenya and Uganda, and PrEP with TDF-FTC among heterosexual men and women in Africa. Of these interventions, PrEP is an attractive policy because it does not directly interferes with the sexual intercourse, providing people a choice on HIV prevention regardless of cultural, religious, or social harnesses.

1. WHO. The strategic use of antiretrovirals to help end the HIV epidemic. Geneva, Switzerland: World Health Organization; 2012.

2. Cohen MS, Chen YQ, McCauley M, Gamble T. Hosseinipour MC, Kumarasamy N. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.

3. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2011: CD009153.

4. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. Aids. 2009; 23: 1397-404.

5. Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, Hargrove J. et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. Plos Med. 2006; 3: e262.

6. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. Plos Med 2005; 2: e298.

7. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN. et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007; 369: 643-56.

8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361: 2209-20.

9. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329: 1168-74.

10. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367: 399-410.

11. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segoladi TM. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367: 423-34.

12. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367: 399-410.

13. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587-99.

14. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV. et al. Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Sci Transl Med 2012; 4: 151ra25.

15. FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection. New Hampshire, USA; 2012.

16. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011; 60: 65-8.

17. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S. et al. Preexposure prophylaxis for HIV infection among African women. New Eng J Med. 2012; 367: 411-22.

18. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K. et al. Bone mineral density in HIV-negative men participating in a Tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. Plos One 2011; 6: e23688.

19. Amico RK, McMaha V, Goicochea P, Vargas L, Marcus JL, Grant RM. et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012; 16: 1243-59.

20. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 2008; 35: 1002-8.

21. Poynten IM, Zablotska I, Grulich AE. Considerations regarding antiretroviral chemoprophylaxis in MSM. Curr Opin HIV AIDS. 2012; 7: 549-56.

22. WHO. Antiretroviral Treatment as Prevention (TasP) of HIV and TB. Geneva, Switzerland: World Health Organization/Departament of HIV/AIDS; June 2012 [cited 2012Oct 01]. Available from:http://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.12_eng.pdf.

23. Beyrer C, Baral SD, van Griensven F, Goodreau SM, Chariyalertsak S, Wirtz AL. et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012; 380: 367-77.

Kallas, E., & João, L. M. (2024). From trials to the public health: pre-exposure prophylaxis for HIV prevention. Colombia Medica, 44(1), 64–65. https://doi.org/10.25100/cm.v44i1.1308

Downloads

Download data is not yet available.
Received 2013-03-05
Accepted 2013-03-05
Published 2024-06-26